top of page
STR3. logo

FAQ.

Healthcare deals and the buying committee.

  • Why do healthcare deals stall after the demo?
    They rarely die with the person you pitched. They die with the stakeholder you never spoke to: IT security, procurement, legal or finance. A committee of eight or more decides the buy, and roughly half hold influence marketing never reaches.

  • Why did my deal go quiet after a strong first meeting?
    A strong first meeting convinces your champion, not the committee behind them. The deal stalls when a hidden stakeholder raises a concern your champion cannot see or answer. Silence usually means an unresolved objection, not lost interest.

  • Who actually decides a healthcare purchase?
    A committee does, not an individual. A typical healthtech or MedTech buy needs alignment across a clinical champion, IT, security, compliance, finance, procurement and sometimes legal and the C-suite. Each holds a veto in practice.

  • What is the biggest reason B2B healthcare deals are lost?
    Most are lost to no decision, not to a competitor. The deal dies from the absence of aligned agreement across stakeholders who never talk to each other about you. That is a trust gap, not a product gap.

  • Why does my champion go silent?
    Champions go quiet when they hit internal resistance they cannot move. They are not in the room when procurement reviews your stability or when security questions your data posture. They cannot transfer conviction they cannot carry.

  • How long is a typical healthcare sales cycle?
    Healthcare and MedTech cycles commonly run months to over a year because of committee review, security and procurement steps. Brand work shortens them by resolving stakeholder concerns before they surface as objections.

  • Why is selling to hospitals and health systems so hard?
    Health systems concentrate risk and process: security, compliance, procurement and clinical governance each gate the buy. A single unresolved concern stalls the deal across the whole chain. You win by being trusted before the review starts.

  • What is a no-decision loss?
    A no-decision loss is a deal that neither closes nor goes to a competitor; it simply stalls out. In healthcare it is the most common outcome, driven by committee members defaulting to caution. Removing reasons to say no is how you prevent it.

  • Why don't more demos fix a stalled pipeline?
    A better demo convinces the champion you already had. It never reaches the stakeholders who were not in the room and who quietly decide. The gap is reach into the committee, not a better pitch.

  • Why doesn't more content move my deals?
    Another whitepaper adds to the noise hidden buyers already ignore. They do not need more to read; they need reasons to trust faster. Trust is built by recognition and proof, not volume.

  • Why does a bigger ad budget not close healthcare deals?
    Reach without resonance buys impressions, not a defensible position inside the committee. Visibility gets you seen; Buyability gets you chosen. The two are not the same.

  • What is the real cost of a stalled healthcare deal?
    Beyond the lost revenue, a stalled deal consumes pipeline, sales time and forecast credibility for quarters. The hidden cost is the next deal that stalls the same way for the same unaddressed reason.

  • If the product is the best, why doesn't it win on its own?
    Because a committee managing risk does not choose the best product; it chooses the safest yes. A superior device or platform with a weak, unfamiliar brand loses to a known alternative the committee already trusts. Merit gets you evaluated; trust across the whole committee gets you chosen. The gap between the two is where good products lose.

  • Is this a sales problem or a marketing problem?
    Usually neither alone, it is a brand problem sitting underneath both. Sales cannot close what the committee does not trust, and marketing cannot generate its way past a position that fails in review. When deals stall in committee, the fix is upstream of both: a brand the whole room recognizes and a message that answers every stakeholder's fear before sales ever gets there.

  • We're doing everything right and still losing deals. What are we missing?
    Often the stakeholders you are not addressing at all. If the demos are strong, the leads are flowing and the deals still stall, the gap is usually the hidden half of the committee, the security, procurement, legal and finance reviewers who never surface in your sales conversations and quietly decide the buy. You are likely doing everything right for the champion and nothing for the room behind them.

  • How do I know if I have a brand problem or a product problem?
    Look at how you lose. If you lose to competitors on features and capability, that may be a product problem. If you lose to no decision, to stalled reviews, to "we went with someone we already knew," that is a brand and trust problem, the committee could not confidently choose you. Most healthcare companies losing deals assume it is the product when the pattern points to trust.

  • What does STR3 actually fix?
    The trust gap that stalls committee-driven healthcare deals. We build the positioning, the brand and the committee-level message that make you the recognizable, defensible, safe choice across every stakeholder who can stall the buy, not just the champion who loves you. In short: we make the brand carry conviction into the rooms your team never enters, so fewer deals go quiet.

The Hidden Buying Committee, by role.

  • What is the Hidden Buying Committee?
    It is the set of stakeholders who shape a healthcare purchase without appearing in your sales conversations: IT security, procurement, compliance, legal and finance. They do not need a reason to say yes; one unresolved concern is enough to say no.

  • What does procurement look for in a healthcare vendor?
    Procurement manages vendor risk, cost and process. They evaluate financial stability, contract terms, references in their peer set and fit with existing vendor frameworks. Missing procurement-ready documentation stalls deals quietly.

  • What does IT security evaluate before buying?
    IT and security assess data handling, access, integration risk and your security posture. Unanswered questions here become silent vetoes. A brand that signals trust and preparedness clears this gate faster.

  • What does compliance care about in a purchase?
    Compliance protects the organization from regulatory and privacy exposure. They look for documentation, sound data practices and a vendor that understands the regulated context. Ambiguity reads as risk.

  • What does legal review in a healthcare deal?
    Legal protects against liability through contract language, data terms and indemnification. Non-standard terms or gaps trigger delay. Predictability and preparedness move you through.

  • What does finance want to know before approving a buy?
    Finance asks what this truly costs, what it returns and how it fits the budget cycle. A champion's enthusiasm does not answer a finance question. A clear value case does.

  • Who is the clinical champion and why do they matter?
    The clinical champion is your internal advocate who has seen the value firsthand. They open the door but cannot close the room alone. Your job is to arm them to carry conviction to people they do not control.

  • Why won't hidden buyers tell me their objection?
    Raising a concern means owning it, so many stakeholders prefer to let a deal lose momentum than voice a veto. The objection stays invisible while the deal dies. Pre-empting concerns is more reliable than chasing them.

  • How do I reach stakeholders I never meet?
    You reach them through brand, not access. When the whole buying group already recognizes and trusts you, your champion is carrying a known name, not selling an unknown one. That is what brand strategy builds.

  • What is the silent veto?
    The silent veto is a stakeholder declining to advance a deal without ever stating why. It looks like delay, reprioritization or a review that never ends. It is the default behavior of a cautious committee.

  • How many people sit on a healthcare buying committee?
    Often eight or more, spanning clinical, technical, security, compliance, finance and procurement roles. Larger or more regulated buys add stakeholders. Each added seat adds a place the deal can stall.

  • How do I map my own buying committee?
    Start from the deal, not the org chart: for a given buy, ask who touches the decision, who can veto it, and whose budget or risk it affects, then name the specific concern each one carries. The stakeholders who never join your calls are usually the ones who decide, so the map has to include the people you do not talk to. Committee mapping is the first move because you cannot build a brand for a room you have not identified.

  • Can I just go around my champion to reach the committee directly?
    Rarely, and usually not well. The champion has internal credibility and context you do not, and going around them can cost you the one advocate you have. The better move is to arm the champion to reach the committee for you, with the specific answers each stakeholder needs, so your case travels through someone the committee already trusts rather than an outside vendor pushing in.

  • What happens when a deal goes quiet after a strong demo?
    It usually means the decision moved into the part of the buy you cannot see: a hidden stakeholder raised a concern, or a silent veto is forming, and the champion may not even know which. Silence is rarely a no from the person you pitched; it is an unresolved concern from someone you never met. The durable fix is a brand that pre-empts those concerns before they surface, not a follow-up sequence chasing a stall.

  • How is a healthcare buying committee different from other B2B committees?
    It carries more veto points and higher stakes. Clinical safety, patient data, regulatory exposure and reimbursement each add a stakeholder with the power to stall, and the cost of a wrong yes, a security breach, a compliance failure, a clinical risk, is higher than in most industries. So the committee is both larger and more cautious, which is exactly why brand trust across every seat matters more in healthcare than almost anywhere else.

  • Can nunNEO show me where I'm losing the committee?
    Yes, that is what the Brand Probe reads. It surfaces which stakeholders your brand reaches and which it loses, where the unresolved concerns sit, and where a silent veto is likely forming, so the Hidden Buying Committee becomes visible instead of guessed at. It turns "the deal went quiet and we do not know why" into a specific, addressable map.

Buyability.

  • What is Buyability?
    Buyability is a framework, originated by the LinkedIn B2B Institute with Bain and Company, that measures how easily buyers can choose your brand. Applied to healthcare, it means making your innovation purchasable across the full buying committee, not just desirable to one buyer. Buyers are 20X more likely to purchase when the whole buying group knows the brand.

  • Who created the Buyability framework?
    The framework originates with the LinkedIn B2B Institute, working with Bain and Company, and is associated with the research of Mimi Turner. STR3 applies it as a north star for healthcare, where the committee is large and the buy is regulated.

  • How is Buyability different from brand awareness?
    Awareness is whether buyers know you exist; Buyability is whether they can choose you without friction. You can be known and still un-buyable if procurement, security or finance have unresolved concerns. Buyability closes those gaps.

  • Why does the whole buying group need to know my brand?
    Because buyers are 20X more likely to purchase when the full group recognizes the brand, not just the champion. Recognition lowers perceived risk for the stakeholders who default to caution. It turns an unknown vendor into a safe choice.

  • How much influence do hidden buyers really have?
    Hidden buyers hold roughly half of all decision influence in a complex B2B purchase. They rarely appear in your CRM, yet they can stall or sink the deal. Ignoring them is ignoring half the room.

  • Are peer recommendations really more powerful than features?
    Yes. A peer recommendation is roughly 3X more powerful than any product feature in a B2B buying decision. Committees trust people like them more than they trust your claims.

  • What is mental availability in healthcare marketing?
    Mental availability is the probability a buyer thinks of your brand when a need arises. Most of the healthcare buying journey happens before vendor contact, so a brand absent from that window never makes the shortlist.

  • Why do most buyers choose the first brand on their shortlist?
    Because the shortlist is largely built before sales contact, from memory and reputation. Most B2B buyers pick from a short list they formed in advance. Being on it, early, is a brand outcome.

  • Is Buyability relevant outside healthcare?
    The principle applies to any committee-driven B2B buy, which is why it holds in adjacent regulated and enterprise markets. STR3 applies it specifically to healthcare, where the committee is larger and the cost of a wrong yes is higher.

  • How do I improve my Buyability?
    By closing the gaps that keep the full committee from choosing you: recognition across every stakeholder, proof that resolves each one's specific risk, and a position clear enough to survive procurement, security and finance. You raise Buyability by making the brand known and trusted in the rooms your team never enters, not by generating more leads. The first step is seeing where you stand, which is what a nunNEO Brand Probe measures.

  • Can Buyability be measured?
    It can be assessed. Buyability shows up in how well the full committee recognizes you, how much unresolved risk each stakeholder carries, and how consistently your position holds across the buying journey. A nunNEO Brand Probe reads those signals and returns a committee-level view of where your brand is buyable and where it breaks, so the concept becomes something you can act on rather than just discuss.

  • What is the difference between Buyability and Deal Risk Insurance?
    Buyability is the goal, a brand the whole committee can confidently choose; Deal Risk Insurance is how STR3 frames the value of getting there. In a high-cost, regulated buy, a brand that answers every stakeholder's fear reduces the risk of the deal stalling or the wrong vendor being chosen. Buyability is the state; Deal Risk Insurance is what that state is worth to a committee managing a consequential purchase.

  • Why do buyers default to the vendor they already know?
    Because in a high-risk buy, the familiar choice feels like the safe choice, even when a better option exists. A committee managing regulatory, financial and clinical risk resolves uncertainty by choosing what it already trusts, which is why an unknown but superior brand loses to a known incumbent. This is the core problem Buyability solves: it makes you the brand the committee already recognizes and trusts before the evaluation even begins.

Brand Strategy Fundamentals.

  • What is healthcare brand strategy?
    Healthcare brand strategy is the work of defining what your company stands for, who it is for and why a regulated buying committee should trust it. It connects positioning, messaging and identity to commercial outcomes. Done well, it shortens cycles and lifts win rates.

  • Why does brand strategy matter for MedTech and healthtech?
    Because the buy is high-risk, multi-stakeholder and slow, brand is what carries trust into rooms your team never enters. A strong brand makes the committee comfortable choosing you. A weak one leaves your champion unarmed.

  • Isn't brand just a logo and colors?
    No. A logo and colors are identity, the surface; brand strategy is the underlying meaning, positioning and trust. The visible layer only works when the strategy beneath it is sound. Foundation before facade.

  • What is the difference between brand and marketing?
    Brand is what people believe about you; marketing is how you reach them. Campaigns spend against a brand, and if the brand is unclear the spend underperforms. Strategy comes first.

  • When should a healthcare startup invest in brand?
    Earlier than most think: before a U.S. launch, before a raise or after a pivot, while positioning is still fuzzy. Fixing brand before scale is cheaper than repositioning after a stalled launch. The cost of waiting is paid in lost deals.

  • What does a brand strategist actually do?
    A brand strategist defines positioning, audience and messaging, then builds the framework that keeps every team and agency aligned. In healthcare, that includes mapping the buying committee and making the position defensible. The output is clarity that drives growth.

  • What is brand architecture?
    Brand architecture is how your master brand, products and sub-brands relate and are named. Clear architecture helps buyers understand what you sell and how it fits. Muddled architecture confuses the committee and dilutes trust.

  • What is a value proposition?
    A value proposition is the specific, defensible reason a buyer should choose you over the alternative, including doing nothing. In healthcare it must hold up to clinical, technical and financial scrutiny. Vague value props stall in committee.

  • What is a brand book or brand guidelines?
    A brand book is the document that keeps every team member and agency consistent: voice, visual system, messaging and usage rules. It prevents drift as you scale. It is how a small team sounds like one brand.

  • How do I know if my brand strategy is working?
    You see it in shorter cycles, higher shortlist inclusion, more stakeholder alignment and fewer no-decision losses. Leading signals include recognition across the committee and a champion who can carry your story without you. Lagging signals show in win rate.

  • We are pre-revenue. Is it too early for brand strategy?
    No, and pre-revenue is often the cheapest time to get it right. Before you have baked positioning into a launched product, a raised deck and a hired sales team, the cost of clarity is low and the cost of getting it wrong compounds. You do not need a full brand system pre-revenue, but you do need a defensible position, because everything downstream inherits it.

  • Can we do brand strategy in-house instead of hiring a studio?
    You can, if you have senior brand judgment on staff and the objectivity to see your own blind spots, which most teams close to the product do not. The value of an outside studio is sector-specific judgment and the distance to name what the internal team is too close to see. Many teams do both: a studio sets the strategy, the in-house team runs it day to day.

  • How is B2B healthcare branding different from consumer branding?
    Consumer branding often wins on emotion and speed; B2B healthcare wins on trust, evidence and the slow consensus of a committee. The buyer is not one person feeling something, it is a group managing risk, so proof and defensibility matter more than emotional pull, though the human element still decides ties. The playbooks do not transfer cleanly, which is why sector experience matters.

  • What is a brand audit?
    A brand audit is a structured assessment of where your brand stands: how it is positioned, how consistently it shows up, and where it is losing the buying committee. It is the diagnosis before the prescription. A nunNEO Brand Probe is our version, reading your brand as the market and the committee actually receive it, and returning the gaps in days rather than a quarter.

  • How does brand strategy connect to revenue?
    Through the buy. A clear, trusted brand shortens the sales cycle, lifts shortlist inclusion, reduces no-decision losses and makes every marketing dollar work harder, each of which shows up in revenue. Brand is not a cost center adjacent to sales; it is what makes the sale easier, faster and more defensible. The return is in deals that would otherwise stall.

Positioning and Messaging. 

  • What is brand positioning?
    Positioning is the place your brand occupies in the buyer's mind relative to alternatives. Strong positioning is specific, true and defensible across the whole committee. Weak positioning sounds like everyone else.

  • Why does my messaging not land with buyers?
    Usually because it speaks in clinical or product terms while the committee thinks in risk, fit and outcomes. Messaging that ignores procurement, security and finance leaves half the room unconvinced. Lead with the buyer's concern, not your feature list.

  • What is a messaging framework?
    A messaging framework is the structured set of positioning statement, value pillars and proof points that every channel draws from. It keeps sales, web and campaigns consistent. It is the source of truth for what you say.

  • How do I message to a buying committee?
    Map each stakeholder's concern and give your champion an answer for each: clinical value, security posture, financial case, compliance fit. One message does not serve eight roles. Defensibility means answering all of them.

  • What is a positioning statement?
    A positioning statement names your audience, your category, your distinct value and your reason to believe, in one disciplined line. It anchors everything downstream. If you cannot write it clearly, the strategy is not done.

  • Why do healthcare brands all sound the same?
    Because they default to the same clinical claims, the same proof language and the same hedged tone. The committee cannot tell them apart, so trust defaults to the incumbent. Distinct positioning is how you break out.

  • How do I differentiate in a crowded healthcare category?
    Differentiate on a truth your competitors cannot claim and the committee actually cares about, then prove it. Feature parity is common; defensible meaning is rare. We build the position that survives scrutiny.

  • What counts as proof in B2B healthcare messaging?
    Proof is the evidence that lowers perceived risk: outcomes, references, security posture, regulatory readiness and peer adoption. In a cautious buy, proof beats persuasion. The committee believes evidence, not adjectives.

  • Should my messaging lead with the product or the problem?
    Lead with the buyer's problem in the buyer's words, then resolve to your brand. Opening with your product makes the page about you, not them. Buyer-led copy converts the committee.

  • How do I message the same product to a clinician, a CFO and IT?
    You do not send one message to all three; you translate one position into each stakeholder's language. The clinician hears clinical outcome, the CFO hears financial case and risk, IT hears security and integration, all expressing the same underlying truth. The discipline is consistency of position with specificity of concern: one brand, answered three ways.

  • What is a value proposition and how is it different from a tagline?
    A value proposition is the substantive promise of what the buyer gets and why it matters, the argument beneath the brand. A tagline is the short, memorable expression of it. Teams often polish the tagline while the value proposition underneath is vague, which is backward: get the promise right, then make it memorable. The committee buys the proposition, not the slogan.

  • Our messaging works for the champion but not the committee. How do we fix it?
    That is the most common gap in healthcare messaging, and it is usually a coverage problem. Your message was built to win the person who loves you, not the four stakeholders who can veto you. The fix is to map the hidden committee, name each one's specific fear, and arm your champion with the answer to each, so the message reaches the room your team never enters.

  • How often should we update our messaging?
    Messaging should hold as long as the position is still true and still differentiated, and change when the market, the competition or your product moves enough to make it stale. Churning it constantly signals a brand still searching for itself; never revisiting it means drifting into sameness as the category shifts. Revisit it at real inflection points, entering a market, launching, repositioning, raising, not on a calendar.

  • Can nunNEO diagnose our messaging and positioning?
    Yes, that is the core of the Brand Probe. It reads where your positioning blurs, where your message drifts across channels, and where the committee stops hearing a reason to choose you. It shows you the gaps between what you mean, what you say and what the committee actually receives, then points to the moves that close them.

Brand Identity and Clinical Monotony.

  • What is Clinical Monotony?
    Clinical Monotony is the sea of sameness in healthcare branding: the same navy-and-teal palettes, the same clinical claims, the same stock imagery. It makes credible companies invisible to the committee. Breaking it is how a brand gets recognized before it is read.

  • Why does my brand look like every other health company?
    Because the category defaults to safe, sterile visual conventions that signal credibility but erase distinctiveness. Looking trustworthy and looking like everyone else are not the same. A distinct system earns recognition.

  • What is brand identity?
    Brand identity is the verbal and visual system that expresses your positioning: name, voice, logo, color, type and imagery. It is the surface that carries the strategy. It works when it is both distinct and consistent.

  • What is verbal identity?
    Verbal identity is how your brand sounds: tone, vocabulary, naming and the guardrails that keep it consistent. In healthcare it balances authority with humanity. It is as much a trust signal as the visual system.

  • What is a design system?
    A design system is the reusable set of visual components and rules that keeps your brand consistent across web, deck and campaign. It lets a small team scale without drift. It is identity made operational.

  • How important is naming in healthcare?
    Naming shapes recognition, recall and how products relate inside your architecture. A clear, distinctive name is an asset; a confusing one is a tax on every conversation. Names should help the committee, not puzzle them.

  • Will a rebrand actually help my company?
    A rebrand helps when the strategy beneath it is the real problem, not the colors. Reskinning a weak position wastes money; fixing the position and then expressing it pays back. Start with strategy, not aesthetics.

  • How do I make a regulated brand feel human?
    By pairing clinical credibility with a voice that respects the patient and the stakeholder as people. Trust in healthcare is emotional as well as evidential. The brands that win feel both rigorous and human.

  • Isn't a safe, clinical look actually what healthcare buyers trust?
    It is what they expect, which is not the same as what wins. A conventional look clears the low bar of looking credible, but it also makes you interchangeable with every competitor clearing the same bar, so the committee defaults to the name it already knows. Distinctiveness and credibility are not a trade-off. The brands that get chosen look trustworthy and unmistakable at once.

  • Can breaking Clinical Monotony hurt us with conservative buyers?
    Not if it is done with judgment rather than for its own sake. Breaking Clinical Monotony is not about looking edgy in a serious category; it is about being recognizable and memorable while still reading as credible to a clinician, a CFO and a procurement lead. The goal is distinction the committee trusts, not distinction that unsettles it. Restraint and recognition, not noise.

  • How does visual identity affect a committee decision?
    More than teams expect, because recognition is a trust shortcut. A committee that recognizes your brand across the buying journey treats it as more established and lower risk, while a forgettable one starts every stakeholder conversation from zero. Identity is not decoration in a committee buy; it is what makes the brand feel known before the evidence is even read.

  • What is brand architecture and when do I need it?
    Brand architecture is how your products, sub-brands and the parent relate, and how they are named and presented together. You need it when a growing portfolio starts confusing buyers, when a new product risks diluting the parent, or when two tiers have to coexist without eroding each other. Done right, it lets a committee understand your whole range at a glance instead of puzzling over how the pieces fit.

  • How does Buyability connect to brand identity?
    Identity is where Buyability becomes visible. Buyability is a brand's defensibility across the full buying committee, and a distinct, consistent identity is one of the levers that builds it: recognition across every stakeholder, trust carried into rooms your team never enters. A strong position with a forgettable identity underperforms its own strategy. The identity is what makes the Buyability real to the committee.

Go-to-market and Demand.

  • What is a go-to-market strategy?
    A go-to-market strategy is the plan for how you reach, convince and win your target buyers, including segmentation, positioning, channels and sales enablement. In healthcare it must account for the committee, not just the lead. GTM without committee strategy stalls.

  • Why do healthcare product launches underperform?
    Often because the brand is not ready for the committee even when the product is ready for the market. The launch reaches the champion but not the stakeholders who gate the buy. Brand readiness is the missing step.

  • What is sales enablement?
    Sales enablement is the set of messaging, content and tools that helps your team carry the brand into the buy. Done right, it arms champions to answer hidden-buyer concerns. It connects brand strategy to closed revenue.

  • How does brand strategy support sales?
    Brand strategy gives sales a defensible story, a recognized name and proof that pre-empts objections. It makes the champion's job easier and the committee's decision safer. Sales closes faster when the brand has done its work.

  • What is demand generation in healthcare?
    Demand generation is the work of creating and capturing buyer interest before and during the buying window. In healthcare most of that window is pre-contact, so brand presence matters more than ad volume. You earn demand by being known and trusted early.

  • Why is my pipeline full but not closing?
    A full pipeline that does not close usually signals a committee problem, not a lead problem. Deals enter on champion interest and stall on hidden-buyer concern. The fix is brand and message work aimed at the whole room.

  • What is the buyer journey in healthcare B2B?
    It runs from problem awareness through shortlist formation to committee review and procurement, with most of it happening before vendor contact. Brand shapes the early, invisible stages. Sales handles the late, visible ones.

  • How do I shorten my sales cycle?
    Resolve stakeholder concerns before they surface by building recognition and proof across the committee. A nunNEO Brand Probe surfaces where trust is missing, and brand work closes those gaps. Cycles shorten when fewer objections survive.

  • What is account-based marketing for healthcare?
    Account-based marketing targets specific high-value accounts and the committee inside them with tailored messaging. In healthcare it pairs well with committee mapping. It works when the brand is recognized by every stakeholder it reaches.

  • What is a GTM Probe and how is it different from a Brand Probe?
    A Brand Probe reads how your brand lands with the buying committee; a GTM Probe reads how your go-to-market carries that brand into the deal, where the message, the motion and the committee are losing momentum. The Brand Probe finds the positioning gaps; the GTM Probe finds where execution drops them. Run the Brand Probe first, then the GTM Probe for the fuller picture.

  • My marketing and sales teams are not aligned. How does that hurt the buy?
    When marketing says one thing and sales says another, the committee hears inconsistency, and inconsistency reads as risk. The champion loses confidence and the hidden stakeholders find another reason to wait. Alignment is a brand problem before it is a process problem: one clear position, carried the same way by everyone who touches the buyer.

  • How do I equip my champion to sell internally when I am not in the room?
    Most of the buy happens without you there, so the champion has to carry your case to legal, IT, procurement and finance alone. That means giving them more than a deck: the specific answers to each stakeholder's fear, in language they can forward. A brand does this at scale, so the champion is armed for the rooms you never enter.

  • We get shortlisted but lose to better-known competitors. Why?
    Being on the shortlist is not the same as being the safe choice, and a committee weighing risk defaults to the name it already trusts. If you keep reaching the final round and losing to a bigger brand, the gap is not your product, it is recognition and trust across the committee, the exact thing Buyability measures. You do not need to be bigger; you need to be the obvious, defensible choice for a specific need.

  • How does content marketing work in a committee-driven buy?
    Not as volume, as targeting. Another generic white paper adds to the noise, but content that answers a specific stakeholder's specific concern, the security question, the finance question, the clinical question, gives your champion something to forward to the person who has it. In a committee buy, the best content is the piece that resolves the objection stalling the deal.

  • Can nunNEO diagnose our go-to-market, not just our brand?
    Yes, that is the GTM Probe. It reads where your go-to-market loses deals: the stage where pipeline stalls, the gap between what marketing says and how sales sells, and the committee friction that kills momentum. Where the Brand Probe diagnoses the brand, the GTM Probe diagnoses the motion that carries it.

U.S. Market Entry.

  • How do European MedTech companies enter the U.S. market?
    Successful entry pairs regulatory readiness with brand readiness: positioning translated for U.S. buyers and a committee that does not yet know you. Many strong European products stall because the brand was not built for the U.S. room. Brand is the entry gap teams underestimate.

  • Why do European health brands struggle in the U.S.?
    Because positioning that works at home often does not translate to U.S. buying committees, channels and expectations. The product is ready; the brand and message are not. Translation, not transliteration, is the work.

  • What does U.S. market entry brand readiness involve?
    It involves translating your positioning for U.S. buyers, mapping the local buying committee, adapting proof and pressure-testing the name and story. A readiness checklist covers the gaps that sink first launches. Readiness is brand, not just regulatory.

  • Should I change my brand for the U.S. market?
    Not necessarily change, but translate and pressure-test it for U.S. buyers, channels and committee expectations. Sometimes the name, claims or proof need adapting. The goal is resonance with a room that does not know you yet.

  • How is U.S. healthcare buying different from Europe?
    U.S. buys often involve larger committees, heavier procurement and security review and different reimbursement and channel dynamics. The cautious, multi-stakeholder pattern is amplified. Brand trust carries more weight, not less.

  • What is the most common U.S. launch mistake?
    Treating the U.S. as a bigger version of the home market and launching with untranslated positioning. The committee reads an unfamiliar brand as risk. The fix is brand readiness before launch, not after the stall.

  • How long does U.S. brand readiness take?
    A focused readiness engagement runs weeks, not quarters, depending on how much positioning translation and committee mapping is needed. A nunNEO Brand Probe surfaces the gaps quickly. The point is to move before launch, not during it.

  • Can STR3 support a transatlantic launch?
    Yes. STR3 works across the U.S. and Europe with dual-market experience, including DACH context. We translate positioning and map the U.S. committee so your launch lands. Founder-led, with on-the-ground market judgment.

  • Do I need a U.S. brand presence before I have a sales team?
    Yes, because the brand shapes the shortlist before any rep makes contact. Arriving unknown means your first sales conversations start from zero trust. A ready brand makes those conversations warmer.

  • Should I hire a U.S. team or lead entry from Europe first?
    Either can work, but the brand has to be ready before you commit either way. Hiring a U.S. team into an untranslated brand means expensive reps starting from zero trust; leading from Europe without a ready brand means the market never learns who you are. Get the positioning and committee map right first, then the team or the remote motion has something to sell into.

  • How much does it cost to enter the U.S. wrong?
    More than getting it right. A stalled launch burns regulatory investment, first-mover timing and the credibility of a second attempt, since a committee that has already filed you as unfamiliar is harder to re-approach. Brand readiness is cheap next to a relaunch. The expensive path is discovering the gap in-market.

  • Do U.S. buyers care that we are a European company?
    It cuts both ways. European origin can signal engineering credibility and quality, or it can read as unfamiliar and untested, depending entirely on how the brand frames it. Handled well, your origin is an asset; left untranslated, it is a question mark the committee resolves by choosing someone they already know. The work is making the origin work for you.

  • We have U.S. FDA clearance but no U.S. brand traction. What now?
    Clearance gets you the right to sell; it does not make the market want to buy. If the clearance is in hand but the pipeline is quiet, the gap is almost always brand readiness: the U.S. committee does not yet know you, trust you or understand why you beat the incumbent. That is a positioning and committee problem, and it is exactly what a Brand Probe surfaces.

  • Can nunNEO assess our U.S. market readiness?
    Yes. The Brand Probe reads your brand as a U.S. buying committee will receive it, surfacing where a European position loses the American room: unfamiliar framing, understated proof, a name or claim that does not land. It shows you the entry gaps in days, before a launch spends months finding them.

EMEA, DACH and Global.

  • Does STR3 work with European healthcare companies?
    Yes. The founder is a dual U.S. and German citizen who has worked the sector on both continents, so STR3 operates across EMEA and the DACH region with genuine fluency on both sides of the Atlantic. Engagements account for local compliance context.

  • What is the DACH region and why does it matter in healthcare?
    DACH covers Germany, Austria and Switzerland, a dense, high-standards healthcare and MedTech market. Brands there face exacting buyers and specific legal expectations. STR3 works with that context directly.

  • Do you account for GDPR and DACH legal requirements?
    Yes, brand and capture work is built with GDPR and DACH expectations in mind, including consent and Impressum considerations. We are not legal counsel, so we align with your compliance team. The point is to respect the rules buyers expect.

  • Can you build a brand that works on both sides of the Atlantic?
    Yes. The work is translating one coherent position across two markets, not running two disconnected brands. Dual-market experience is core to how STR3 operates. Consistency builds trust; localization builds resonance.

  • How do cultural differences affect healthcare branding?
    Tone, proof expectations, regulatory framing and trust signals differ by market, even when the product does not. A claim that reassures one committee can read as overreach to another. Localization is a trust exercise, not just translation.

  • Which markets does STR3 serve?
    Primarily the United States and Europe, with focus on the DACH region. The work spans MedTech, HealthTech and oral health across both. Engagements are remote-first with senior, founder-led involvement.

  • We are a European company entering the U.S. What changes about our brand?
    More than you expect. The U.S. buying committee is larger, more risk-averse and reads credibility differently: American buyers want proof, references and a confident, specific claim where a European brand often leads with understatement. The work is keeping what made you trusted at home while making the brand legible to a committee that judges by different signals. Your technology travels; your positioning has to be rebuilt for the room.

  • Why do successful European healthcare brands stall in the U.S.?
    Usually not the product, the translation. A brand tuned for a German or European buyer can read as too modest, too technical or too unfamiliar to a U.S. committee, so it never earns the shortlist. The fix is not louder marketing, it is a position an American committee can immediately understand and trust.

  • We are a U.S. company expanding into Europe. What do we need to know?
    That the confident, claim-forward American style can read as overreach to a European committee, and that DACH buyers in particular expect precision, proof and respect for local norms including GDPR and Impressum. A brand that wins in the U.S. often needs its tone and proof recalibrated, not rebuilt, to earn European trust. Localization is where the deal is won or lost.

  • Why does founder dual citizenship matter for our brand?
    Because cross-Atlantic brand work fails on the nuances a translator or an outsider misses: how a German committee reads confidence versus overreach, what proof a Swiss buyer expects, when American directness helps and when it costs the deal. A dual U.S. and German citizen who has sold in both markets carries that judgment natively, not secondhand. It is the difference between a brand that travels and one that gets lost in translation.

  • Do you understand both the U.S. and German healthcare systems?
    Yes. They differ in structure, reimbursement, buyer expectations and regulatory framing, and a brand tuned for one can misread the other entirely. Two decades in the sector across both markets, with citizenship in each, means the work is grounded in how buyers actually decide in each system, not a generic international playbook.

  • Can you represent our brand credibly to German-speaking buyers?
    Yes. The founder is a native German speaker and German citizen, so the positioning, tone and proof are built for how DACH buyers actually evaluate, with the precision and restraint that market expects. DACH buyers can tell immediately whether a brand understands them. That fluency is built in, not outsourced.

  • We are a DACH company and want to look credible in the U.S. without losing our identity. Can you do that?
    That is exactly the work. The goal is not to Americanize your brand until it is unrecognizable, but to make what makes you trusted at home legible to a U.S. committee that judges credibility differently. A dual-citizen perspective keeps both sides honest: enough American confidence to earn the shortlist, enough of your original identity to stay authentically you.

  • Do you travel or work on the ground in Europe?
    Engagements are remote-first, which keeps senior, founder-led involvement efficient across time zones, with on-the-ground presence in Europe as the engagement warrants. The dual-citizen, dual-market background means the cultural context is present in every session regardless of location. Proximity helps; fluency is what actually carries the work.

  • Can nunNEO diagnose a brand for a specific market?
    Yes. The Brand Probe reads your brand as a given market's committee receives it, so a European company can see how an American committee will perceive the brand, or a U.S. company can see where it will lose a European one. It surfaces the market-specific gaps before you spend a launch discovering them.

MedTech and Diagnostics.

  • How is MedTech branding different from other B2B branding?
    MedTech branding carries clinical, regulatory and patient-safety weight that generic B2B does not. The committee is larger and more risk-averse, and proof matters more than persuasion. The brand has to earn trust before it earns attention.

  • How do I position a medical device for a buying committee?
    Position it on a clinically meaningful, defensible benefit, then arm your champion to answer security, procurement and finance. A device that wins on a demo can still stall on an unanswered stakeholder concern. Defensibility is the work.

  • What is FDA-compliant positioning and messaging?
    It is positioning and claims framed to stay within regulatory bounds while still being clear and compelling. STR3 builds messaging that respects those limits; we are not regulatory counsel and align with yours. The aim is credible, compliant clarity.

  • How do I differentiate a diagnostics company?
    Differentiate on the outcome and trust your buyers care about, not just assay performance, then prove it across the committee. Many diagnostics sound interchangeable to non-clinical stakeholders. A clear position translates the science into a reason to choose.

  • Why do strong medical products still lose deals?
    Because the buy is decided by a committee weighing risk, not only by the clinical merit of the product. A superior device with a weak brand loses to a known, trusted alternative. The gap is Buyability, not capability.

  • How do I sell MedTech to procurement and value-analysis committees?
    Give them the documentation, references and financial case they need to say yes without owning hidden risk. Value-analysis committees default to caution, so remove reasons to decline. Brand recognition lowers the perceived risk before review.

  • What branding do MedTech startups need before a raise?
    A clear position, a defensible story and proof that the brand can carry the committee, since investors probe go-to-market risk. A nunNEO Brand Probe names the blind spots before an investor does. Brand readiness is part of fundability.

Dental and Oral Health.

  • Do you work with dental and oral health companies?
    Yes. Oral health is a core focus, including dental SaaS, 3D printing and device brands. The founder spent 20 years across leading dental companies including Straumann, Formlabs Dental and Carestream Dental. We know the buyers and the buying patterns.

  • How is dental SaaS branding different?
    Dental SaaS sells to practices and DSOs where clinical, operational and financial stakeholders all weigh in. The buy blends software evaluation with practice trust. Positioning has to speak to both the clinician and the operator.

  • What is a DSO and why does it matter for branding?
    A DSO is a dental service organization that manages the business side of multiple practices, concentrating buying decisions. Selling to a DSO means selling to a committee, not a single dentist. Brand trust scales the conversation.

  • How do I sell into DSOs specifically?
    Map the decision structure, because a DSO concentrates clinical, operational and financial evaluation into a central committee. Your champion may be a clinician, but procurement, operations and finance decide at scale. Brand trust is what carries the pitch across all of them.

  • How do I market to dentists and practice owners?
    Speak to clinical outcomes and practice realities, and earn trust through peers and proof, since recommendations carry heavy weight. Dentists trust other dentists more than claims. Brand presence in the profession shapes the shortlist.

  • How do I brand a dental 3D printing or device company?
    Position on the clinical and workflow value clinicians and labs actually feel, and break the category sameness visually. Many dental device brands blur together. A distinct, credible identity earns recognition.

  • Everyone in our category looks the same. How do we stand out?
    Category sameness is the default in dental devices and 3D printing, where brands converge on the same clinical look and the same feature language. Differentiation comes from a distinct, credible identity and a position built on the outcome clinicians and labs actually feel, not the specification sheet. We call the trap Clinical Monotony, and breaking it is how a brand gets recognized before it is read.

  • How do I brand for both clinicians and dental labs?
    They value different things: clinicians care about chair time and clinical outcome; labs care about workflow, fit and reliability. A brand that serves both connects the technology to the result each one feels, and proves it with peer adoption on both sides. One story, two proofs.

  • What proof matters most in oral health buying?
    Peer adoption, clinical outcomes and practical workflow evidence carry the most weight with clinical buyers. The committee trusts demonstrated results over messaging. Proof is the centerpiece, not the footnote.

  • Can nunNEO diagnose a dental or oral health brand?
    Yes. The Brand Probe reads any healthcare brand at the committee level, and dental is a core focus. For a dental SaaS, device or 3D printing brand, it surfaces where you are losing the clinician, the operator or the DSO committee, and the moves to fix it.

HealthTech and Digital Health SaaS.

  • How do I brand a digital health platform?
    Brand it on the outcome it delivers and the trust it earns from clinical, security and financial stakeholders, not on feature breadth. Digital health buys hinge on data trust and adoption risk. Position to lower both.

  • Why do healthtech SaaS deals stall in security review?
    Because data handling and integration risk raise unresolved questions that security treats as reasons to wait. A brand that signals trust and preparedness clears review faster. The work is removing reasons to say no.

  • How do I sell health SaaS to hospitals?
    Map the committee, arm your champion and bring procurement-ready proof, since hospital buys gate on security, compliance and finance. Clinical interest opens the door; stakeholder trust closes it. Brand carries trust into rooms you never enter.

  • Does product-led growth work in healthcare?
    Product-led growth can build champions, but in regulated healthcare it still meets a committee at the point of purchase. It does not bypass procurement or security. Brand and message still decide the committee outcome.

  • How do I position an interoperability or data platform?
    Position on the trust and outcome the buyer gets, not the plumbing, then prove security and reliability to the committee. Technical buyers care about the plumbing; the committee cares about risk and result. Translate accordingly.

  • How does branding reduce churn in health SaaS?
    A clear brand sets the right expectations and attracts right-fit buyers, which lowers mismatch churn. Buyers who understood the value stay longer. Brand strategy pays back at acquisition and again at renewal.

  • What do healthtech investors look for in brand and GTM?
    Investors look for a defensible position, evidence of committee-level demand and a credible go-to-market story. A weak brand reads as go-to-market risk. Brand readiness supports the raise.

Health AI.

  • How do I brand a Health AI company?
    Brand it on the trustworthy outcome it delivers and the rigor behind it, not on the model. Health AI buyers weigh trust, evidence and risk heavily. The brand has to make a novel technology feel safe to choose.

  • Why is trust the central issue for Health AI brands?
    Because buyers fear opacity, error and liability more than they doubt capability. An AI that cannot show its reasoning reads as risk to a cautious committee. Brands win by making rigor and trust visible.

  • How do I position AI in healthcare without overpromising?
    Position on demonstrated value and human oversight, and let the proof carry the claim. Overpromising triggers skepticism in a risk-averse buy. Restraint signals credibility.

  • How do I sell AI tools to a skeptical clinical committee?
    Lead with evidence, transparency and the human-in-the-loop, and address safety and data concerns before they are raised. Clinical committees veto on unresolved risk. Trust is the unlock, not novelty.

  • What is the black-box problem in Health AI buying?
    The black-box problem is buyers distrusting an AI whose reasoning they cannot see. Opacity becomes a reason to say no. Brands that show their reasoning convert better.

  • How does STR3 use AI in its own work?
    As scaffolding, not spotlight: AI amplifies human insight without replacing the strategist. Our nunNEO diagnostic tools surface patterns; people make the call. The principle is AI as Ally.

Working with STR3.

  • What does STR3 do?
    STR3 is a boutique healthcare brand and strategy studio for MedTech, HealthTech and oral health companies. We build brands that close in committee, not just brands that look good in a deck. Every engagement is founder-led.

  • Who does STR3 work with?
    Founders, CMOs, VPs of Marketing and GTM leads at MedTech, HealthTech, oral health and Health AI companies. We work with teams entering the U.S., launching, repositioning or raising. The common thread is a committee-driven buy.

  • What industries does STR3 serve?
    Oral health, MedTech, HealthTech, Health AI and premium consumer health, across the U.S. and Europe.

  • What services does STR3 offer?
    Brand Foundation, Brand Expression, Advisory and Embedded Strategy, and AI-Driven Marketing Systems built on nunNEO. Each maps to a buyer moment: entering, launching, repositioning or raising. You start where your growth needs you to.

  • How do I start with STR3?
    It starts with a conversation. We pressure-test your positioning and name the gaps costing you deals. It is direct and built to tell you where the leverage is. You leave with a clearer read, not a pitch.

  • How does a typical engagement work?
    We diagnose the gaps, frame a Defensible Strategy, then forge the positioning, identity and enablement to express it. Engagements stay founder-led and embedded long enough to make the work stick. The arc is Probe, Frame, Forge.

  • What is the Probe, Frame, Forge model?
    Probe diagnoses where your brand is losing the committee. Frame builds the Defensible Strategy. Forge produces the positioning, naming and enablement. It is the same diagnostic-to-production rhythm that runs through nunNEO: diagnosis feeds the build.

  • What deliverables do I get?
    Depending on scope: a brand audit, positioning and messaging framework, voice guide, visual identity system, persona and committee mapping, and a brand book. Each engagement lists its deliverables up front. The point is work you can use in sales, decks and on the site.

  • Is STR3 a good fit for early-stage companies?
    Yes, when positioning is still fuzzy and you are heading into a launch, raise or market entry. Fixing brand early is cheaper than repositioning after a stall. We scope to stage.

  • How is STR3 structured as a studio?
    It is a boutique, founder-led studio with a network of senior strategists, designers and specialists assembled per engagement. You get senior judgment, not a junior team. Lean by design.

  • Does STR3 offer fractional CMO support?
    Yes, through Advisory and Embedded Strategy, which gives you fractional-CMO depth without a full-time hire. We set strategy and stay embedded through launch and market entry. Senior judgment in the room when it counts.

Pricing, Timeline and ROI. 

  • How much does a healthcare brand strategy engagement cost?
    Engagements scale from a focused diagnostic to embedded fractional-CMO support, priced by scope. A nunNEO Brand Probe returns committee-level findings in days, rather than the drawn-out quarter a traditional strategy retainer takes. Start the conversation for a scoped recommendation.

  • Are engagements fixed-price?
    Engagements are scoped and priced up front, so you know the deliverables and the investment before you start. Fixed scope keeps the work predictable. No open-ended retainers by default.

  • How long does a brand strategy engagement take?
    A focused sprint runs about six weeks; a full foundational brand system runs about eight. A nunNEO Brand Probe compresses the diagnostic that used to take a quarter into days. Market entry and regulatory review extend timelines.

  • What is the ROI of brand strategy in healthcare?
    The return shows up as shorter cycles, higher shortlist inclusion and fewer no-decision losses, each of which protects revenue. Brand is Deal Risk Insurance for a high-cost buy. The cost of a weak brand is the deals it quietly loses.

  • Is brand strategy worth it for a small company?
    Yes, often more so, because a small team cannot afford stalled deals or a launch that misses. Clarity is the cheapest growth move a small company has. It also makes every later marketing dollar work harder.

  • What is the lowest-commitment way to start with STR3?
    A nunNEO Brand Probe is the lowest-commitment entry, surfacing the gaps before any larger engagement. It tells you where the leverage is. You can scale up from there.

  • How does STR3 measure success?
    By the commercial signals that matter: shorter cycles, more committee alignment, higher win rate and fewer no-decision losses. We set the markers with you at the start. Brand work is judged on the buy, not on applause.

  • Will I see results quickly?
    A nunNEO Brand Probe gives you findings in days, and message and positioning changes can lift conversations soon after. Full brand outcomes build over the cycle as recognition compounds. Early signals are real; the full payoff accrues.

  • How does a nunNEO Brand Probe compare to a traditional audit?
    A Brand Probe returns committee-level findings in days, where a traditional research-heavy audit takes a quarter. It is the focused way to see your gaps before committing to a larger engagement. Start the conversation to scope it.

Comparisons.

  • Why hire a healthcare-only studio instead of a generalist agency?
    Because healthcare is a regulated, committee-driven buy that rewards sector judgment a generalist does not carry. A generalist agency is built on everything, which makes it expert in nothing. We bring clinical and regulatory fluency to the work.

  • What is the difference between STR3 and a big branding agency?
    A big agency gives you scale and often a junior team; STR3 gives you senior, founder-led judgment focused on healthcare. You trade breadth for depth and accountability. Your brand is never handed off.

  • Should I hire an agency or build an in-house brand team?
    In-house gives you continuity; an outside studio gives you senior, sector-specific judgment without a full-time hire. Many teams use both: a studio to set strategy, in-house to run it. The right mix depends on stage.

  • Fractional CMO or agency: which do I need?
    An agency executes briefs; a fractional CMO sets strategy and owns the outcome from inside your team. STR3 works as the latter through Advisory and Embedded Strategy. You get ownership, not just output.

  • Should I hire a freelancer or a studio?
    A freelancer can execute a task; a studio brings strategy, a senior network and accountability for the outcome. For a committee-driven healthcare buy, the strategy is the hard part. That is where a studio earns its keep.

  • Why not just use a generic AI marketing tool?
    Generic tools generate output; they do not diagnose brand defensibility across a healthcare buying committee. nunNEO is built for that specific problem and grounds findings in trust, recognition and preference. A tool built for everything is expert in nothing.

  • How is STR3 different from a marketing consultancy?
    STR3 joins strategy with brand and identity, and grounds both in committee-level diagnosis through nunNEO. Many consultancies advise but do not build. We diagnose, frame and forge.

  • What makes STR3 a boutique rather than a full-service agency?
    Boutique means senior-led, focused and lean by design, with a network assembled per engagement rather than a fixed staff to feed. You get depth on your problem, not a roster to fill.

Founder and Advisors.

  • Who is Philipp Striebe?
    Philipp Striebe is the founder of STR3. A former Director of Global Marketing, Sensei SaaSat Carestream Dental and commercial leader at Formlabs Dental and Straumann Group, he brings 20 years in MedTech and oral health to the brands he builds. He specializes in translating complex technologies into clear narratives.

  • What is Philipp Striebe's background?
    Two decades in healthcare, including senior commercial and marketing roles at Straumann Group, Formlabs Dental and Carestream Dental. He works across the U.S. and Europe. His focus is brand and go-to-market for healthcare innovation.

  • Who leads engagements at STR3?
    The founder leads every engagement; your brand is not handed to a junior team. A senior network supports the work as needed. Founder-led is the model, not a tagline.

  • Does STR3 have an advisory board?
    Yes: Andreas Nitschke for Organizational Excellence, Mario Wagner for Visual Identity and Gaurav Manchanda for Healthcare Innovation. They bring systems, design and innovation perspective to the work.

  • Why is founder-led important for brand work?
    Because senior judgment in the room is what a high-stakes, regulated buy demands. Junior execution on a complex healthcare brand is where strategy gets lost. Founder-led means accountability for the outcome.

nunNEO.

  • What is nunNEO?
    nunNEO is STR3's proprietary brand intelligence tool for healthcare. It runs the committee-level analysis that used to take a quarter and countless research hours, surfacing the blind spots, message drift and positioning conflicts costing you pipeline, then handing you prioritized moves.

  • What does nunNEO do?
    It diagnoses where your brand is losing the buying committee and turns the findings into moves you can act on. It names the gaps your team is too close to see. See what your team can't.

  • How is nunNEO different from generic AI tools?
    Generic tools count mentions or generate copy; nunNEO diagnoses brand defensibility across the full buying committee. Every finding is grounded in what drives trust, recognition and preference in healthcare. You see the reasoning, not just an output.

  • What is a Brand Probe?
    A Brand Probe is the nunNEO diagnostic that surfaces your brand's blind spots, message drift and positioning conflicts at the committee level. It returns findings in days. It is the focused way to see where you are losing the room.

  • What is a GTM Probe?
    A GTM Probe applies the same diagnostic lens to your go-to-market: where the committee, message and motion are losing deals. It pairs with the Brand Probe for a fuller picture. Diagnosis comes before production.

  • What are Brand Forge and GTM Forge?
    Forge is the production layer that turns diagnosis into output: positioning, naming, identity and enablement. Where the Probe reveals, the Forge builds. The diagnostic layer feeds the production layer.

  • Is my data safe with nunNEO?
    nunNEO is built for healthcare, where trust is the product, and it shows its reasoning rather than operating as a black box. Your responses are processed securely, never sold or shared. For specifics on data handling for your engagement, start the conversation and we will align with your security and compliance teams.

  • How do I start a nunNEO Brand Probe?
    Start your Brand Probe at the nunNEO intake on the STR3.AI page. Findings come back in days. It is the lowest-commitment way to see your gaps.

bottom of page